Deciphera Pharmaceuticals, Inc.
(NASDAQ : DCPH)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.00%205.101.2%$477.70m
GILDGilead Sciences, Inc.
0.91%75.510.9%$401.46m
BIIBBiogen Inc.
1.22%345.411.3%$352.23m
CELGCelgene Corporation
-0.66%87.721.2%$341.18m
ILMNIllumina, Inc.
0.52%358.163.5%$248.76m
REGNRegeneron Pharmaceuticals, Inc.
0.78%390.282.6%$232.51m
VRTXVertex Pharmaceuticals Incorporated
-0.24%180.081.9%$168.98m
EXASExact Sciences Corporation
1.72%76.2825.3%$162.68m
SRPTSarepta Therapeutics, Inc.
-3.43%147.5916.4%$129.44m
AAgilent Technologies, Inc.
-0.58%70.721.5%$124.93m
VKTXViking Therapeutics, Inc.
-4.06%18.200.9%$115.92m
ALXNAlexion Pharmaceuticals, Inc.
-2.10%121.992.0%$114.40m
NKTRNektar Therapeutics
0.96%59.005.6%$106.74m
BMRNBioMarin Pharmaceutical Inc.
-2.55%97.844.4%$97.41m
ALNYAlnylam Pharmaceuticals, Inc
-0.67%94.579.7%$93.14m

Company Profile

Deciphera Pharmaceuticals, Inc. operates as a biotechnology company which develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.